The Fungal Infections Diagnosis Market size was estimated at USD 9.90 billion in 2025 and expected to reach USD 10.60 billion in 2026, at a CAGR of 7.18% to reach USD 16.09 billion by 2032.

Fungal infections diagnosis is now a frontline priority in infectious disease testing, antimicrobial resistance control, intensive care, oncology, transplant medicine, HIV care, and hospital infection prevention. The need is driven by the documented burden of invasive fungal diseases, with WHO reporting more than 6.5 million invasive fungal infections and 3.8 million associated deaths each year, while the WHO fungal priority pathogens list identifies critical, high, and medium-priority fungi and calls for stronger laboratory capacity, surveillance, innovation, and public health action. In practical terms, the diagnostic focus is shifting from delayed culture-dependent confirmation toward earlier fungal pathogen identification, antifungal susceptibility testing, Candida auris screening, Aspergillus galactomannan testing, beta-D-glucan testing, Histoplasma antigen detection, cryptococcal antigen screening, molecular assays, and integrated mycology surveillance.

The fungal infections diagnosis landscape is being reshaped by three structural shifts: rising recognition of underdiagnosed invasive fungal disease, accelerating antifungal resistance, and the operational need for rapid results in high-risk patients. WHO’s 2025 diagnostic landscape analysis states that products for diagnosing invasive fungal diseases and determining antifungal susceptibility have lagged behind diagnostics for priority bacterial infections, while access remains uneven, particularly in low- and middle-income countries. At the same time, resistant Candida auris and resistant Aspergillus, Candida, and other priority fungal pathogens are pushing laboratories to pair species-level identification with susceptibility workflows, because only a limited number of antifungal drug classes are available for invasive disease management.

Operationally, the most important transformation is the move from episodic mycology testing to connected diagnostic pathways. Hospitals are increasingly using risk-based screening, reflex testing from positive blood cultures, non-culture antigen assays, nucleic acid amplification, and reference-laboratory confirmation to reduce missed cases and support infection prevention.

Artificial intelligence is creating a cumulative rather than disruptive impact in fungal infections diagnosis. Its highest-value applications are expected around digital microscopy support, histopathology image triage, radiology pattern recognition for fungal pneumonia, automated signal detection in laboratory information systems, antifungal resistance analytics, genomic epidemiology, and outbreak surveillance. A systematic review of AI-based fungal diagnostic tools found active progress in precision and efficacy assessment across clinical contexts, but the field still requires stronger external validation, representative datasets, workflow integration, and clinically explainable outputs before broad adoption in routine mycology.

The regulatory and governance context is equally important. The FDA’s public AI-enabled medical device list shows that AI tools authorized for use in the United States have undergone applicable premarket safety and effectiveness review, while WHO guidance emphasizes that AI in health can improve diagnosis, treatment, research, drug development, surveillance, and outbreak response only when ethics, human rights, accountability, and governance are built into design and deployment. For fungal infection diagnosis, this means AI should augment laboratory professionals, prioritize high-risk flags, reduce time-to-review, and strengthen surveillance without replacing validated mycology methods or clinical judgment.

Asia-Pacific is defined by pathogen diversity, high-risk populations, and uneven access to advanced mycology testing. Talaromyces marneffei is endemic in South-East Asia and parts of China and India, and WHO notes that it can account for up to one in six hospital admissions in affected people living with HIV, while India’s COVID-associated mucormycosis surge documented 40,824 reported mucormycosis cases by the end of June 2021, reinforcing the importance of early microscopy, histopathology, culture, imaging, and molecular confirmation in diabetes, steroid exposure, and immunocompromised care pathways. North America combines advanced laboratory infrastructure with rising surveillance pressure: CDC estimates that fungal diseases in the United States are associated each year with approximately 7,288 deaths, 133,555 hospitalizations, and more than 13 million outpatient visits, and Canada’s sentinel hospital data recorded 43 Candida auris isolates from 2020 to 2024, including 14 in 2024. Latin America requires diagnostic strategies that address both healthcare-associated resistant yeasts and endemic mycoses; PAHO/WHO reports that histoplasmosis is among the most frequent fungal opportunistic infections in people living with HIV in the Americas and may be responsible for 5–15% of AIDS-related deaths in the region, while Brazil faces hyperendemic zoonotic sporotrichosis and important paracoccidioidomycosis burden. Europe is moving toward stronger regional preparedness as ECDC documented 4,012 Candida auris cases in EU/EEA countries from 2013 to 2023 and warned that spread can progress rapidly through hospital networks, while the United Kingdom reported 212 Candida auris cases in 2024 and made laboratory reporting a strengthened surveillance priority. The Middle East is increasingly focused on Candida auris recognition and outbreak control, with confirmed reports across Gulf and neighboring countries and continuing data scarcity across the Arabian Peninsula, creating a need for standardized species identification and susceptibility testing. Africa faces the strongest equity imperative: WHO reported 26.3 million people living with HIV in the African Region in 2024, Africa CDC highlighted a continental fungal diagnostic capacity survey covering 18 diagnostic areas, and reviews of Candida auris in Africa identified more than 2,500 cases across six countries, underscoring the need for cryptococcal antigen screening, Histoplasma antigen access, reference mycology laboratories, and infection-control-linked surveillance.

ASEAN-focused fungal infections diagnosis should prioritize decentralized antigen testing, HIV-associated opportunistic mycoses, and referral pathways for Talaromyces marneffei, because talaromycosis is endemic in Southeast Asia and affects people with advanced HIV and other immunocompromising conditions. GCC strategies should emphasize Candida auris readiness, candidemia surveillance, and laboratory standardization, since regional reviews describe data scarcity across Bahrain, Kuwait, Qatar, Oman, Saudi Arabia, and the United Arab Emirates, while documented Candida auris activity in the broader Middle East highlights the importance of validated identification and antifungal susceptibility testing. European Union priorities are anchored in harmonized reporting, reference-laboratory confirmation, outbreak staging, and cross-border preparedness, supported by ECDC data showing 4,012 EU/EEA Candida auris cases from 2013 to 2023 and rapid progression to regional endemicity in some healthcare networks. BRICS-oriented diagnostic planning should be segmented by pathogen ecology and care setting: Brazil requires endemic mycosis and sporotrichosis diagnostics, India requires mucormycosis readiness, China faces talaromycosis and resistant yeast detection needs, Russia has documented Candida auris reports in the scientific literature, and South Africa is central to African Candida auris surveillance and candidemia monitoring. G7 health systems have the capacity to lead validation of fungal molecular diagnostics, AI-assisted workflows, and resistance reporting, but they also show continuing pressure from Candida auris and yeast bloodstream infections in the United States, Canada, the United Kingdom, Japan, Germany, France, Italy, and Spain. NATO-relevant diagnostic preparedness should focus on cross-border patient transfers, military and civilian hospital readiness, and interoperable reporting because ECDC explicitly links Candida auris control to improved detection, infection-control precautions, and preparedness for inter-hospital and cross-border transmission.

The United States is a high-priority diagnostic environment because CDC estimates substantial annual fungal disease mortality, hospitalization, and outpatient burden, while national Candida auris clinical cases reached 6,304 in 2024. Canada’s country insight is focused on early containment: national sentinel hospitals reported 43 Candida auris isolates from 2020 through 2024, including growth from four cases in 2020 to 14 in 2024, and Canadian guidance emphasizes infection prevention and control in healthcare settings. Mexico is shaped by both endemic fungal risk and resistant yeast emergence, including a multicentric Candida auris outbreak from 2020 to 2023 in which 32.4% of initially colonized cases progressed to infection. Brazil requires strong diagnostic coverage for paracoccidioidomycosis, described as the most important systemic mycosis in Brazil, and zoonotic sporotrichosis, described as hyperendemic and a serious public health issue. The United Kingdom is strengthening Candida auris surveillance after 212 cases were reported in 2024 and laboratory reporting requirements were introduced to improve public health response. Germany, France, Italy, and Spain should continue aligning laboratory detection with European surveillance; ECDC reported 4,012 EU/EEA Candida auris cases from 2013 to 2023, noted rapid healthcare-network spread, and identified Spain, Italy, and Germany among countries with higher reported case numbers. Russia remains relevant to resistant yeast surveillance because Candida auris infections have been reported there in peer-reviewed global epidemiology literature. China and India require broad mycology capacity for talaromycosis, Candida auris, and other invasive fungal diseases, while India also demonstrated the severe diagnostic and clinical consequences of COVID-associated mucormycosis. Japan remains historically important because Candida auris was first documented there in 2009, and South Korea is important because early bloodstream infection cases and 61 clinical isolates across 13 hospitals were documented in national studies. Australia’s priority is rapid notification and containment, with Victoria classifying Candida auris as an urgent notifiable condition and requiring immediate pathology notification on suspected or confirmed diagnosis.

Industry leaders should prioritize evidence-based fungal infection diagnosis pathways that connect clinical risk stratification, validated laboratory testing, infection prevention, and resistance reporting. The first action is to implement reflex species-level identification and susceptibility testing for invasive Candida, suspected Candida auris, Aspergillus in high-risk respiratory disease, cryptococcal disease in advanced HIV, and endemic mycoses in relevant geographies. The second action is to embed Candida auris screening and reporting protocols into admission, transfer, intensive care, long-term acute care, and outbreak workflows, because public health agencies consistently identify rapid detection and infection-control linkage as essential.

The third action is to expand non-culture testing where evidence supports clinical use, including cryptococcal antigen, Histoplasma antigen, Aspergillus galactomannan, beta-D-glucan, molecular assays, and point-of-care or near-patient tools for settings where culture is too slow or insensitive. The fourth action is to adopt AI only through governed, validated, auditable workflows that improve triage, quality control, and surveillance while preserving expert review. The fifth action is to invest in training, external quality assessment, reference-laboratory networks, and interoperable dashboards that can translate fungal diagnostic results into timely antifungal stewardship and infection prevention decisions.

The research methodology used for this executive summary triangulated verified public health guidance, surveillance updates, peer-reviewed studies, and technical reports from recognized health authorities and indexed scientific literature. Priority was given to WHO fungal priority pathogen materials, WHO’s 2025 fungal diagnostic landscape analysis, CDC burden and Candida auris surveillance, ECDC Candida auris surveillance, PAHO/WHO histoplasmosis guidance, national public health guidance, and peer-reviewed evidence on endemic mycoses, mucormycosis, talaromycosis, sporotrichosis, and AI-enabled fungal diagnostic tools.

Evidence was weighted by recency, public health authority, methodological transparency, and clinical relevance. Surveillance data were used only to describe observed disease burden, reported cases, diagnostic gaps, and preparedness needs. No disease burden claims were converted into commercial estimates, and no sizing, share, or future projection language was used. The synthesis also excluded named manufacturers and sales-led claims, focusing instead on disease epidemiology, diagnostic technology categories, laboratory workflows, regional access gaps, and actionable operational implications for fungal infections diagnosis.

Fungal infections diagnosis is entering a decisive phase in which earlier pathogen detection, antifungal susceptibility testing, Candida auris screening, endemic mycosis recognition, and AI-supported surveillance can materially improve patient safety and outbreak readiness. The evidence shows that invasive fungal diseases carry a major global mortality burden, diagnostic product development and access remain uneven, and resistant fungal pathogens are exposing gaps in laboratory capacity, infection prevention, and cross-border reporting.

The strongest path forward is not a single test but an integrated diagnostic ecosystem: risk-based clinical suspicion, rapid non-culture assays, molecular confirmation, species-level identification, susceptibility testing, reference-laboratory support, ethical AI enablement, and real-time public health reporting. Organizations that build these capabilities around validated evidence will be better positioned to reduce missed diagnoses, accelerate appropriate antifungal therapy, detect resistance earlier, and strengthen healthcare-associated infection control across regions, groups, and countries.